Design controls software centralizes traceability, automates requirements traceability matrix (RTM) generation, and structures Design History File (DHF) evidence so it survives an audit instead of getting reconstructed the night before one. It matters most for regulated software, Class II/III devices, and Software as a Medical Device (SaMD), where 21 CFR 820.30 and IEC 62304 both govern documentation depth. This gap is commonly observed in early-stage healthtech teams.
TL;DR:
- Ensure the design controls software provides bidirectional traceability and exports that are compatible with your quality management system to avoid audit issues.
- Confirm that the software integrates with your existing development tools, ALM, CI/CD pipelines, and enforces role-based access controls to maintain data integrity and security.
- Use a risk-based, CSA-aligned validation approach that focuses on high-risk functions, rather than validating every feature equally, to streamline validation efforts.
- Map the top requirements and high-risk functions before implementation to prevent retrospective DHF reconstruction and reduce audit-related delays.
- Verify vendor validation summaries and specific system support during evaluations, avoiding vague claims of "full traceability" or "seamless integration" to prevent misaligned expectations.
Table of Contents
- What Does Design Controls Software Actually Do?
- How Do Inputs, Outputs, Verification, and Validation Connect?
- What Do 21 CFR 820.30 and IEC 62304 Actually Require?
- How Should You Evaluate Design-Controls Software Before Buying?
- How Do You Roll Out Design Controls Software Without Losing Momentum?
- What Does a Practitioner Actually See Startups Get Wrong?
- Where Should Regulatory Leaders Focus First?
- How The StartupMD Helps Teams Build Compliant Products Faster
- Sources
What Does Design Controls Software Actually Do?
Spreadsheets track data. Design controls software tracks relationships, and that distinction is the whole point. The core capability is linking every design input to its corresponding output, and every output to the verification or validation activity that proves it works.
That includes RTM management (mapping user needs to requirements to test cases), DHF assembly (compiling the regulatory record FDA guidance treats as the central audited artifact), structured design review workflows, and change control that flags downstream impact when a requirement shifts.
The functional gap between spreadsheets and purpose-built tools shows up in three places:
- Real-time gap analysis, flagging an untested requirement the moment it's added, not during a pre-audit scramble
- Toolchain integration, connecting to Application Lifecycle Management (ALM) platforms, CI/CD pipelines, and test systems so evidence updates automatically instead of through manual re-entry
- Bidirectional traceability, letting a reviewer start from a test case and trace backward to the requirement it validates, or start from a requirement and trace forward to its evidence
Manual spreadsheet tracking works until a product has more than a few dozen requirements. Past that point, the update burden alone creates the version-control errors auditors flag most often.
How Do Inputs, Outputs, Verification, and Validation Connect?
Design inputs are measurable criteria: what the device or software must do, expressed in testable terms. Design outputs are the technical artifacts that satisfy those criteria, source code, architecture diagrams, algorithms, specifications. Confusing the two is a common early mistake. "The app must be easy to use" is not a design input. "The app must let a user complete medication logging efficiently and within a reasonable time frame" is.
Design-controls software forces that discipline by requiring a linked output before a requirement can be marked complete, and by requiring linked evidence before the output itself can close, as described in detail by Our services — Vicedomini Softworks.
The practical workflow breaks down into four connected steps:
- Capture design inputs as discrete, measurable requirements rather than narrative goals
- Link each input to a design output, the specific artifact built to satisfy it
- Verify that the output meets the input's specification (does the code do what the spec said?)
- Validate that the finished product meets the user's actual need in real-world conditions (does it solve the clinical problem?)
Verification and validation get confused constantly, but they answer different questions. Verification checks the build against the spec. Validation checks the spec against reality.
Underneath all of this sits configuration management: version control for every artifact, including third-party and open-source components, known formally as Software of Unknown Provenance (SOUP). The FDA's own guidance recommends documenting software development plans, configuration baselines, and version history as standard DHF content, not optional extras.
Pro Tip: Version every artifact the moment it's created, not when a release ships. Retroactive versioning is where most SOUP inventories fall apart during audit prep.
What Do 21 CFR 820.30 and IEC 62304 Actually Require?
FDA's design control regulation lays out the procedural skeleton every device manufacturer must maintain, and it maps cleanly onto software features:
- Design and development planning, documented and updated as the project evolves
- Design input procedures, ensuring requirements are appropriate and address the intended use
- Design output procedures, ensuring outputs can be verified against inputs
- Design review, formal, documented, at defined stages
- Design verification and validation, including software validation where applicable
- Design transfer and design changes, with documented impact analysis
- The Design History File, compiling the complete record for every one of the above
IEC 62304 provides software-specific requirements classified by software safety classes indicating increasing levels of documentation and testing rigor according to potential harm severity. Design-controls software should allow scaling documentation depth based on classification without applying a single template to all projects.
This is also where Computer Software Assurance (CSA) reframes the conversation. Rather than validating every feature of every tool with equal intensity, CSA directs validation effort toward high-risk functions, an approach The StartupMD has covered in depth for healthtech teams weighing how much rigor their tool validation actually needs.
How Should You Evaluate Design-Controls Software Before Buying?
Vendor demos look polished. Audit trails don't lie. The evaluation gap between the two is where procurement decisions go wrong, so build the checklist around evidence, not features.
- Confirm bidirectional traceability, not one-directional linking that only works forward from requirement to test
- Request a sample RTM export in the format your quality management system (QMS) or notified body actually accepts
- Verify integration depth with your existing development toolchain, ALM, issue trackers, CI/CD, not just a generic API claim
- Check role-based access controls, confirming the tool enforces who can approve, edit, or close a design record
- Ask for the vendor's own validation summary, documentation of how they validated the tool for its intended use
- Confirm data security attestations relevant to your quality system, including audit logging and record retention
Red flags cluster around vague language. "Full traceability" without a sample export. "Seamless integration" without naming the specific systems supported. "Validated" without a summary document to review. Any vendor unwilling to produce a real RTM export or test-traceability example during evaluation is asking you to buy on faith.
Pro Tip: Ask for a validation summary, not a certificate. A certificate proves someone signed something. A summary proves someone tested it.
How Do You Roll Out Design Controls Software Without Losing Momentum?
Start with one product or module, not the entire portfolio at once. Map existing artifacts before importing anything, so the tool reflects reality rather than aspiration.
- Pilot on a single product line and expand only after the RTM structure proves workable
- Involve cross-functional reviewers (engineering, QA, clinical, regulatory) before finalizing workflows, not after
- Validate the tool using a CSA-aligned, risk-based approach, focusing effort on the high-risk functions your team actually relies on, not every minor feature
- Maintain an active SOUP and toolchain inventory, treating the development environment itself as part of the DHF, since ungoverned build tools can call design-output integrity into question during an audit
What Does a Practitioner Actually See Startups Get Wrong?
Early, measurable design inputs pay off downstream. When requirements are written as testable statements from the start, verification stops being a scramble and becomes a checklist. The teams that skip this step end up reconstructing DHF evidence retrospectively, which is slower, costlier, and far more likely to produce audit findings than documenting continuously as work happens.
The other recurring mistake: treating SOUP and toolchain validation as an afterthought instead of a governed part of the quality system. Fractional clinical leadership can help by unifying three things that startups usually manage in silos: user needs, risk analysis, and regulatory evidence.
Design controls aren't a compliance tax bolted onto engineering. They're the mechanism that forces a team to define what "done" means before writing a single line of code, and that discipline shows up in fundraising diligence as much as in FDA submissions.
Where Should Regulatory Leaders Focus First?
Traceability discipline and risk-based validation aren't separate workstreams from product quality. They're the same workstream, and treating them as one accelerates both regulatory readiness and investor diligence. Map your ten highest-priority requirements and one high-risk function this week, then use that map to pressure-test any vendor's fit before signing anything.
— Paul Bergeron MD, MBA
How The StartupMD Helps Teams Build Compliant Products Faster
Choosing the right software solves half the problem. Aligning that tool with clinical strategy, regulatory sequencing, and investor expectations solves the other half, and that's where a fractional Chief Medical Officer earn their seat at the table.
The StartupMD works with healthcare SaaS founders and healthtech executives to build regulatory readiness into product strategy from day one, not bolt it on before a submission deadline. That means helping teams structure DHF practices that hold up under audit, apply CSA-aligned validation proportionate to actual risk, and unify clinical, regulatory, and product evidence into one coherent story for investors. If your team is evaluating design-controls software, mapping SaMD requirements, or preparing for a raise where regulatory maturity will get scrutinized, explore The StartupMD's advisory services and start the conversation about what a fractional CMO engagement looks like for your stage.
Sources
- 21 CFR § 820.30 - Design controls. | Electronic Code of Federal Regulations (e-CFR) | LII / Legal Information Institute
- Design Controls (FDA guidance) - PDF